Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SHPH
SHPH | US
0.92
USD0.05
5.58%
SHPH | US
About SHPH
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
06/03/2026
Close
0.92
Open
0.85
High
1.03
Low
0.80
Shuttle Pharmaceuticals Holdings Inc. a clinical stage pharmaceutical company develops novel therapies to cure cancers. It develops Ropidoxuridine an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161 an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225 a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303 a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville Maryland.
View LessSHPH | US
Risk
120.5
Sharpe
-0.80
Luna's Score
40/100
Recommendation
Sell
Luna says (SHPH | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
86.2%1 month
120.5%3 months
149.1%6 months
130.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.37
Debt to equity
1.44
Debt to assets
0.41
Ent. to EBITDA
-0.67
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-5.74M
MarketCap
2.70M
MarketCap(USD)
2.70M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-186.00
Short ratio
0.03
Short perc.
1.94
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.39
Range1M
1.01
Range3M
3.64
Volumes: Market Activity
Rel. volume
2.44
Price X volume
272.83K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.67 | 24.85 | Cheaper |
| Ent. to Revenue | - | 361.91 | - |
| PE Ratio | - | 30.05 | - |
| Price to Book | 4.37 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 149.12 | 65.24 | Riskier |
| Debt to Equity | 1.44 | -1.88 | Expensive |
| Debt to Assets | 0.41 | 0.48 | Par |
| Market Cap | 2.70M | 3.71B | Emerging |
